OncoMatch/Clinical Trials/NCT06720987
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Is NCT06720987 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including KQB365 and Cetuximab for kras g12c mutation.
Treatment: KQB365 · Cetuximab — The goal of this clinical trial is to learn if KQB365 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB365. The main questions it aims to answer are: * What is the safe dose of KQB365 by itself or in combination with cetuximab? * Does KQB365 alone or in combination with cetuximab decrease the size of the tumor? * What happens to KQB365 in the body? Participants will: * Receive KQB365 infusion weekly alone or in combination with cetuximab * Visit the clinic about 9 times in the first 6 weeks, and then once every week after that.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Colorectal Cancer
Biomarker criteria
Required: KRAS g12c
Required: KRAS g12s
Disease stage
Metastatic disease required
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic, Phoenix · Phoenix, Arizona
- Sarah Cannon Cancer Institute at HealthONE · Denver, Colorado
- Mayo Clinic, Jacksonville · Jacksonville, Florida
- Dana Farber Cancer Institute · Boston, Massachusetts
- START Midwest · Grand Rapids, Michigan
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify